Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
NovoMix 30 Insulin aspart/insulin aspart protamine Diabetes mellitus Do not list Complete
Nplate Romiplostim Chronic immune (idiopathic) thrombocytopenic purpura (ITP) Do not list Complete
Nubeqa Darolutamide non-metastatic castration resistant prostate cancer (nmCRPC) Reimburse with clinical criteria and/or conditions Complete
Nubeqa darolutamide Metastatic castration-sensitive prostate cancer Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Severe chronic rhinosinusitis with nasal polyps Reimburse with clinical criteria and/or conditions Complete
Nucala Mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Eosinophilic granulomatosis with polyangiitis Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Nucala mepolizumab Asthma, severe eosinophilic (pediatric) Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Nucynta tapentadol hydrochloride pain, severe Do not reimburse Complete